Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Oncology · Papillary and Follicular Thyroid Carcinoma

Staging and Risk: Understanding Your Outlook

At a Glance

Thyroid cancer staging uses the AJCC system based on age and tumor spread to predict survival, while the ATA risk system predicts the likelihood of cancer returning. Because survival rates are high, treatment focuses heavily on minimizing recurrence through therapy like TSH suppression.

After a thyroid cancer diagnosis, your medical team will use two different systems to describe your situation. While they both use the word “risk,” they are measuring two very different things: mortality (the risk of dying from the disease) and recurrence (the risk of the cancer coming back).

AJCC TNM Staging: Predicting Survival

The AJCC 8th Edition staging system is used primarily to predict your long-term survival [1]. Thyroid cancer is unique because age is a major factor in how it behaves. The current system uses a cutoff of 55 years old [2].

  • If you are under age 55: Your mortality risk is exceptionally low. Even if the cancer has spread to nearby lymph nodes, you are still classified as Stage I [3]. You only move to Stage II if the cancer has spread to distant parts of the body, such as the lungs or bones.
  • If you are age 55 or older: The stages range from I to IV based on the size of the tumor (T), whether it is in the lymph nodes (N), and if it has spread to distant organs (M) [2].

ATA Risk Stratification: Predicting Recurrence

Because most people with differentiated thyroid cancer have a nearly normal life expectancy, your doctors focus more on the ATA Risk Stratification (or similar updated guidelines) [4]. The 2015 guidelines established a three-tier system, and recent 2025 ATA updates have introduced a refined four-tier system to even better predict recurrence [5][6]. This system helps determine how aggressive your treatment needs to be to keep the cancer from returning.

ATA Risk Category Typical Features Impact on Treatment
Low Risk Small tumor, no distant spread, and favorable clinical/pathological features [7]. Often can avoid Radioactive Iodine (RAI) [8]; TSH goal is usually near normal or mildly suppressed [9].
Intermediate Risk Microscopic growth outside the thyroid (extrathyroidal extension) or vascular invasion [10][11]. RAI is often considered based on individual factors; TSH goal is typically slightly suppressed.
High Risk Gross (visible) growth into nearby structures, distant metastasis, or large cancerous lymph nodes [4][12]. RAI is standard; strict TSH suppression (below 0.1 mIU/L) is usually required [13].

Dynamic Risk Stratification: Your Risk Can Change

It is important to know that these categories are not permanent. Your doctor will use Dynamic Risk Stratification (DRS) to re-evaluate you during follow-up, typically 1 to 2 years after initial treatment [14]. If your blood tests (Thyroglobulin) and ultrasounds remain clear, you may be re-classified into an “Excellent Response” category, allowing your doctor to safely reduce the intensity of your hormone suppression and monitoring [15][16].

A Note on TSH Suppression

Thyroid-stimulating hormone (TSH) can act like “fuel” for any remaining thyroid cancer cells. By taking a slightly higher dose of thyroid hormone, your TSH level is lowered (suppressed) [17]. While this helps prevent recurrence, long-term TSH suppression can carry risks like heart palpitations, atrial fibrillation, and bone thinning (osteoporosis), especially in older adults [18]. Your TSH target is a careful balance between these risks and the risk of the cancer returning [19].

Common questions in this guide

What is the difference between thyroid cancer staging and risk stratification?
Staging predicts your long-term survival, while risk stratification estimates the chance of the cancer coming back. Because survival rates for differentiated thyroid cancer are very high, doctors often focus more on your recurrence risk to plan treatment.
How does age affect my thyroid cancer stage?
In the AJCC staging system, age is a major factor for thyroid cancer. If you are under 55, your mortality risk is considered exceptionally low, and you are classified as Stage I unless the cancer has spread to distant parts of the body like the lungs or bones.
What is ATA risk stratification?
The American Thyroid Association (ATA) risk stratification is a system that predicts how likely your thyroid cancer is to return. It classifies patients into low, intermediate, or high risk based on tumor size, spread, and other specific features.
Why do I need to suppress my TSH levels after thyroid cancer?
Thyroid-stimulating hormone (TSH) can act like fuel, encouraging any remaining thyroid cancer cells to grow. By taking a slightly higher dose of thyroid hormone medication, your TSH levels are lowered, which helps prevent the cancer from returning.
Can my thyroid cancer risk category change over time?
Yes, your doctor will use Dynamic Risk Stratification to re-evaluate your condition during follow-up visits. If your ultrasounds and blood tests stay clear, you may be moved to a lower risk category, which can safely reduce the need for intense monitoring and TSH suppression.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Am I considered Stage I or Stage II under the AJCC 8th edition, and how does my age affect that classification?
  2. 2.What is my specific ATA Risk Category (Low, Intermediate, or High), and what factors from my pathology report led to that ranking?
  3. 3.Based on my risk of recurrence, is Radioactive Iodine (RAI) actually necessary, or can we safely monitor me with ultrasound?
  4. 4.What is my 'target TSH' level for the next year? How does this goal balance my risk of recurrence against my risk of heart issues or bone loss?
  5. 5.When will we perform our first 'Dynamic Risk Stratification' to see if we can lessen the intensity of my TSH suppression?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    The effects of the Union for International Cancer Control/American Joint Committee on Cancer Tumour, Node, Metastasis system version 8 on staging of differentiated thyroid cancer: a comparison to version 7.

    Verburg FA, Mäder U, Luster M, Reiners C

    Clinical endocrinology 2018; (88(6)):950-956 doi:10.1111/cen.13597.

    PMID: 29573277
  2. 2

    Patient Age Is an Independent Risk Factor of Relapse of Differentiated Thyroid Carcinoma and Improves the Performance of the American Thyroid Association Stratification System.

    Trimboli P, Piccardo A, Signore A, et al.

    Thyroid : official journal of the American Thyroid Association 2020; (30(5)):713-719 doi:10.1089/thy.2019.0688.

    PMID: 31973653
  3. 3

    Comparison of long-term prognosis for differentiated thyroid cancer according to the 7th and 8th editions of the AJCC/UICC TNM staging system.

    Kim K, Kim JK, Lee CR, et al.

    Therapeutic advances in endocrinology and metabolism 2020; (11()):2042018820921019 doi:10.1177/2042018820921019.

    PMID: 32489582
  4. 4

    Concepts of Pathological Staging and Prognosis in Papillary Thyroid Carcinoma.

    Lam AK

    Methods in molecular biology (Clifton, N.J.) 2022; (2534()):109-119 doi:10.1007/978-1-0716-2505-7_8.

    PMID: 35670971
  5. 5

    Comparison of 2015 and 2025 ATA Risk Stratification Systems for Predicting Recurrence in Papillary Thyroid Carcinoma.

    Yoo JH, Lee S, Kim BR, et al.

    Annals of surgical oncology 2026; doi:10.1245/s10434-026-20381-1.

    PMID: 42570987
  6. 6

    Clinical implication of the 2025 ATA risk stratification in follicular thyroid carcinoma: A comparison with the 2015 ATA risk stratification.

    Park H, Kim BR, Yoo JH, et al.

    Oral oncology 2026; (175()):107912 doi:10.1016/j.oraloncology.2026.107912.

    PMID: 41771233
  7. 7

    Current Management of Low Risk Differentiated Thyroid Cancer and Papillary Microcarcinoma.

    Tarasova VD, Tuttle RM

    Clinical oncology (Royal College of Radiologists (Great Britain)) 2017; (29(5)):290-297 doi:10.1016/j.clon.2016.12.009.

    PMID: 28087101
  8. 8

    Dynamic risk assessment in patients with differentiated thyroid cancer.

    Pitoia F, Jerkovich F

    Endocrine-related cancer 2019; (26(10)):R553-R566.

    PMID: 31394499
  9. 9

    Is Maintaining Thyroid-Stimulating Hormone Effective in Patients Undergoing Thyroid Lobectomy for Low-Risk Differentiated Thyroid Cancer? A Systematic Review and Meta-Analysis.

    Won HR, Jeon E, Chang JW, et al.

    Cancers 2022; (14(6)) doi:10.3390/cancers14061470.

    PMID: 35326621
  10. 10

    Additional Surgery for Occult Risk Factors After Lobectomy in Solitary Thyroid Nodules is Predicted by Cytopathology Classification and Tumor Size.

    Flagg A, Rooper L, Sheth S, et al.

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2020; (26(7)):754-760 doi:10.4158/EP-2019-0473.

    PMID: 33471644
  11. 11

    Prediction mode of more than 5 central lymph nodes metastases in clinically node-negative ipsilateral papillary thyroid carcinoma with tumor size 1 to 4 cm.

    Jin L, Sun HL, Zhou L, et al.

    Medicine 2020; (99(16)):e19809 doi:10.1097/MD.0000000000019809.

    PMID: 32311998
  12. 12

    High-dose radioactive iodine therapy is associated with decreased risk of recurrence in high-risk papillary thyroid cancer.

    Gray KD, Bannani S, Caillard C, et al.

    Surgery 2019; (165(1)):37-43 doi:10.1016/j.surg.2018.04.059.

    PMID: 30274732
  13. 13

    The role of the hypothalamic-pituitary-thyroid axis in thyroid cancer.

    Abaandou L, Ghosh R, Klubo-Gwiezdzinska J

    The lancet. Diabetes & endocrinology 2025; (13(4)):333-346 doi:10.1016/S2213-8587(24)00364-4.

    PMID: 39870098
  14. 14

    Usefulness of dynamic risk stratification in pediatric patients with differentiated thyroid carcinoma.

    Kim K, Kim WW, Choi JB, et al.

    Annals of surgical treatment and research 2018; (95(4)):222-229 doi:10.4174/astr.2018.95.4.222.

    PMID: 30310805
  15. 15

    Initial and Dynamic Risk Stratification of Pediatric Patients With Differentiated Thyroid Cancer.

    Sung TY, Jeon MJ, Lee YH, et al.

    The Journal of clinical endocrinology and metabolism 2017; (102(3)):793-800 doi:10.1210/jc.2016-2666.

    PMID: 27809646
  16. 16

    2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

    Haugen BR, Alexander EK, Bible KC, et al.

    Thyroid : official journal of the American Thyroid Association 2016; (26(1)):1-133 doi:10.1089/thy.2015.0020.

    PMID: 26462967
  17. 17

    Thyroid Hormone Suppression Therapy.

    Biondi B, Cooper DS

    Endocrinology and metabolism clinics of North America 2019; (48(1)):227-237 doi:10.1016/j.ecl.2018.10.008.

    PMID: 30717904
  18. 18

    Thyroid-Stimulating Hormone Suppression Therapy in Thyroid Cancer: Balancing Benefits and Harms.

    Pishdad R, Ahmadi S

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2026; (32(3)):401-405 doi:10.1016/j.eprac.2025.12.002.

    PMID: 41407103
  19. 19

    Cardiovascular Outcomes of Differentiated Thyroid Cancer Patients on Long Term TSH Suppression: A Systematic Review and Meta-Analysis.

    Yu J, Kaur R, Ayeni FE, et al.

    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 2023; (55(6)):379-387 doi:10.1055/a-2084-3408.

    PMID: 37295414

This page explains thyroid cancer staging and risk stratification for educational purposes only. Discuss your specific stage, recurrence risk, and treatment plan with your endocrinologist or oncologist.

Get notified when new evidence is published on thyroid gland papillary and follicular carcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.